President and CEO
Camargo Pharmaceutical Services
Kenneth Phelps relied on more than three decades of experience
in the health science and services industry to found Camargo
Pharmaceutical Services in 2003. As an expert in end-to-end drug
development, specifically the 505(b)(2) regulatory approval
pathway, Phelps and his team attain two to five pre-IND meetings
before the FDA per month. Aiding companies across more than 25
countries, Camargo provides successful FDA approval of numerous
drug products each year.
Before founding Camargo, his broad background in drug
development had led to a number of executive-level assignments in
the areas of quality control, project management and regulatory,
clinical and medical affairs at Duramed Pharmaceuticals, Inc. (now
Teva Pharmaceuticals).
Prior to his work for Duramed, Phelps held a number of positions
at Merrell National Labs, which merged to become Merrell Dow and
eventually evolved into Sanofi-Aventis. At Merrell he had global
responsibility for quality assurance, quality control and
processing technology with an assignment based in Milan, Italy. He
later directed IT for multinational manufacturing operations,
leading to technical improvements in R&D, accounting and
manufacturing operations.